205 related articles for article (PubMed ID: 32927398)
1. 12-months prospective Pentraxin-3 and metabolomic evaluation in multiple sclerosis patients treated with glatiramer acetate.
Signoriello E; Iardino P; Casertano S; De Lucia D; Pucciarelli A; Puoti G; Chiosi E; Lus G
J Neuroimmunol; 2020 Nov; 348():577385. PubMed ID: 32927398
[TBL] [Abstract][Full Text] [Related]
2. IL-27: a potential biomarker for responders to glatiramer acetate therapy.
Mindur JE; Valenzuela RM; Yadav SK; Boppana S; Dhib-Jalbut S; Ito K
J Neuroimmunol; 2017 Mar; 304():21-28. PubMed ID: 27449853
[TBL] [Abstract][Full Text] [Related]
3. Predictive cytokine biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis.
Valenzuela RM; Kaufman M; Balashov KE; Ito K; Buyske S; Dhib-Jalbut S
J Neuroimmunol; 2016 Nov; 300():59-65. PubMed ID: 27390072
[TBL] [Abstract][Full Text] [Related]
4. Chitinase 3-like 1 is associated with the response to interferon-beta treatment in multiple sclerosis.
Matute-Blanch C; Río J; Villar LM; Midaglia L; Malhotra S; Álvarez-Cermeño JC; Vidal-Jordana A; Montalban X; Comabella M
J Neuroimmunol; 2017 Feb; 303():62-65. PubMed ID: 28063616
[TBL] [Abstract][Full Text] [Related]
5. Use of glatiramer acetate between 2010-2015: effectiveness, safety and reasons to start GA as first or second line treatment in Swiss multiple sclerosis patients.
Zecca C; Disanto G; Sacco R; Riccitelli GC; Gobbi C
BMC Neurol; 2019 Jul; 19(1):159. PubMed ID: 31299922
[TBL] [Abstract][Full Text] [Related]
6. Induction of apoptosis in CD4(+) T-cells is linked with optimal treatment response in patients with relapsing-remitting multiple sclerosis treated with Glatiramer acetate.
Boziki M; Lagoudaki R; Melo P; Kanidou F; Bakirtzis C; Nikolaidis I; Grigoriadou E; Afrantou T; Tatsi T; Matsi S; Grigoriadis N
J Neurol Sci; 2019 Jun; 401():43-50. PubMed ID: 31009931
[TBL] [Abstract][Full Text] [Related]
7. Phosphorylated SIRT1 as a biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis.
Ciriello J; Tatomir A; Hewes D; Boodhoo D; Anselmo F; Rus V; Rus H
Exp Mol Pathol; 2018 Oct; 105(2):175-180. PubMed ID: 30028960
[TBL] [Abstract][Full Text] [Related]
8. SIRT1 as a potential biomarker of response to treatment with glatiramer acetate in multiple sclerosis.
Hewes D; Tatomir A; Kruszewski AM; Rao G; Tegla CA; Ciriello J; Nguyen V; Royal W; Bever C; Rus V; Rus H
Exp Mol Pathol; 2017 Apr; 102(2):191-197. PubMed ID: 28109694
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of Delayed-release Dimethyl Fumarate on Clinical and Patient-reported Outcomes in Patients With Relapsing Multiple Sclerosis Switching From Glatiramer Acetate: RESPOND, a Prospective Observational Study.
Kresa-Reahl K; Repovic P; Robertson D; Okwuokenye M; Meltzer L; Mendoza JP
Clin Ther; 2018 Dec; 40(12):2077-2087. PubMed ID: 30470580
[TBL] [Abstract][Full Text] [Related]
10. A differential sex-specific pattern of IgG2 and IgG4 subclasses of anti-drug antibodies (ADAs) induced by glatiramer acetate in relapsing-remitting multiple sclerosis patients.
Avila S; Guerrero-García JJ; Becerril-Villanueva E; Pérez-Sánchez G; Pavón L; Rojas-Mayorquín AE; Mireles-Ramírez MA; Muñoz-Valle JF; Vallejo-Castillo L; Medina-Rivero E; Ortuño-Sahagún D; Pérez-Tapia SM
Mult Scler Relat Disord; 2019 Sep; 34():92-99. PubMed ID: 31272071
[TBL] [Abstract][Full Text] [Related]
11. Tolerability and Safety of Combined Glatiramer Acetate and N-Acetylcysteine in Relapsing-Remitting Multiple Sclerosis.
Schipper HM; Arnold D; GrandʼMaison F; Melmed C; Moore F; Levental M; Su H; Constantin M; Stril JL; Godin J
Clin Neuropharmacol; 2015; 38(4):127-31. PubMed ID: 26166235
[TBL] [Abstract][Full Text] [Related]
12. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009333. PubMed ID: 27880972
[TBL] [Abstract][Full Text] [Related]
13. Differential glatiramer acetate treatment persistence in treatment-naive patients compared to patients previously treated with interferon.
Fernández-Fournier M; Tallón-Barranco A; Chamorro B; Martínez-Sánchez P; Puertas I
BMC Neurol; 2015 Aug; 15():141. PubMed ID: 26286576
[TBL] [Abstract][Full Text] [Related]
14. QualiCOP: real-world effectiveness, tolerability, and quality of life in patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate, treatment-naïve patients, and previously treated patients.
Ziemssen T; Calabrese P; Penner IK; Apfel R
J Neurol; 2016 Apr; 263(4):784-91. PubMed ID: 26914926
[TBL] [Abstract][Full Text] [Related]
15. Differential Transcription of SOCS5 and SOCS7 in Multiple Sclerosis Patients Treated with Interferon Beta or Glatiramer Acetate.
Rojas-Morales E; Santos-López G; Hernández-Cabañas S; Arcega-Revilla R; Rosas-Murrieta N; Jasso-Miranda C; El-Kassis EG; Reyes-Leyva J; Sedeño-Monge V
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31905601
[TBL] [Abstract][Full Text] [Related]
16. The Effect of Glatiramer Acetate on Retinal Nerve Fiber Layer Thickness in Patients with Relapsing-Remitting Multiple Sclerosis: A Longitudinal Optical Coherence Tomography Study.
Zivadinov R; Tavazzi E; Hagemeier J; Carl E; Hojnacki D; Kolb C; Weinstock-Guttman B
CNS Drugs; 2018 Aug; 32(8):763-770. PubMed ID: 29767815
[TBL] [Abstract][Full Text] [Related]
17. Biological activity of glatiramer acetate on Treg and anti-inflammatory monocytes persists for more than 10years in responder multiple sclerosis patients.
Spadaro M; Montarolo F; Perga S; Martire S; Brescia F; Malucchi S; Bertolotto A
Clin Immunol; 2017 Aug; 181():83-88. PubMed ID: 28642148
[TBL] [Abstract][Full Text] [Related]
18. Assessment of CCL27 and IL-11 in Multiple Sclerosis Patients Treated with Interferon-β and Glatiramer Acetate.
Ebrahimi Monfared M; Shapoori S; Mosayebi G; Khansarinejad B; Ghazavi A; Rezagholizamenjany M; Ganji A
Neuroimmunomodulation; 2019; 26(6):301-306. PubMed ID: 31935737
[TBL] [Abstract][Full Text] [Related]
19. Effect of glatiramer acetate on cerebral grey matter pathology in patients with relapsing-remitting multiple sclerosis.
Crescenzo F; Marastoni D; Zuco C; Pitteri M; Magliozzi R; Monaco S; Calabrese M
Mult Scler Relat Disord; 2019 Jan; 27():305-311. PubMed ID: 30453199
[TBL] [Abstract][Full Text] [Related]
20. Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis.
Honce JM; Nair KV; Sillau S; Valdez B; Miravalle A; Alvarez E; Schreiner T; Corboy JR; Vollmer TL
Neurology; 2019 Feb; 92(7):e723-e732. PubMed ID: 30635477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
